POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise in Hard-to-Treat stomach cancer
Disease control OngoingThis early-stage trial tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help control advanced gastroesophageal cancer that cannot be surgically removed. The study enrolled 16 participants and aims to see if the combination can make the c…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Virus therapy joins chemo-radiation in fight against esophageal cancer
Disease control OngoingThis early-phase trial is testing whether adding a cancer-killing virus (OBP-301) to standard chemotherapy and radiation is safe for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The study involves 16 participants and focuses on side effects …
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 11, 2026 12:08 UTC
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC